Health Care·Pharmaceuticals·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.29 | N/A | -0.69% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.29 | N/A | -0.69% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions. They highlighted the importance of adapting strategies to navigate these challenges.
Management acknowledged the challenges faced in the quarter.
They emphasized a need for strategic adjustments moving forward.
The earnings report indicates that Terns Pharmaceutical is facing difficulties, particularly reflected in the EPS miss. The stock's 5.23% decline suggests investor disappointment and uncertainty about the company's future performance. Without guidance, investors may remain cautious as they assess the company's next steps.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENDEAVOUR SILVER COR
Mar 11, 2024